<DOC>
	<DOCNO>NCT00802906</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy initial subthreshold retinal micropulselasercoagulation versus single intravitreal 1.5mg bevacizumab injection central serous choriretinopathy , micropulse selectively treat damage RPE induce reproliferation healthy RPE cell , whereas intravitreal injection non-selectively stop RPE leakage .</brief_summary>
	<brief_title>Bevacizumab Versus Micropulse Central Serous Chorioretinopathy ( CSC )</brief_title>
	<detailed_description>To evaluate clinical efficacy initial subthreshold retinal micropulselasercoagulation twelve eyey per group versus single intravitreal 1.5mg bevacizumab injection central serous choriretinopathy , micropulse selectively treat damage RPE induce reproliferation healthy RPE cell . BCVA EDTRS score , OCT , leakage FLA , static perimetry group correlate control group without treatment 10 month .</detailed_description>
	<mesh_term>Central Serous Chorioretinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion criterion : CSC &gt; 4 month duration History macular chorioretinal inflammation Lens / corneal opacity</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>micropulselaserphotocoagulation</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>CSC</keyword>
</DOC>